Last reviewed · How we verify
A Multiple-Dose, Double Blind, Double Dummy, Comparative Bioavailability Study of Two Formulations of Bupropion Hydrochloride 300 mg Extended Release Tablets Under Fasting Conditions
The objective of this study is to evaluate the comparative bioavailability between bupropion hydrochloride 300 mg extended release tablets (Teva Pharmaceuticals USA) and Wellbutrin XL® 300 mg extended release tablets (Biovail Pharmaceuticals, Inc.) at steady-state in patients under fasting conditions.
Details
| Lead sponsor | Teva Pharmaceuticals USA |
|---|---|
| Phase | Phase 1 |
| Status | TERMINATED |
| Enrolment | 8 |
| Start date | 2010-01 |
Conditions
- Depressive Disorder
Interventions
- Bupropion HCl
- Bupropion HCl
Primary outcomes
- Comparative bioavailability — 1 month
Countries
United States